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Background. The Musculoskeletal Tumor Society (MSTS) scoring system measures function and is commonly used but criticized
because it was developed to be completed by the clinician and not by the patient. We therefore evaluated if there is a difference
between patient and clinician reported function using the MSTS score. Methods. 128 patients with bone metastasis of the lower
(𝑛 = 100) and upper (𝑛 = 28) extremity completed the MSTS score. The MSTS score consists of six domains, scored on a 0 to 5
scale and transformed into an overall score ranging from 0 to 100% with a higher score indicating better function.TheMSTS score
was also derived from clinicians’ reports in the medical record. Results. The median age was 63 years (interquartile range [IQR]:
55–71) and the study included 74 (58%) women. We found that the clinicians’ MSTS score (median: 65, IQR: 49–83) overestimated
the function as compared to the patient perceived score (median: 57, IQR: 40–70) by 8 points (𝑝 < 0.001). Conclusion. Clinician
reports overestimate function as compared to the patient perceived score. This is important for acknowledging when informing
patients about the expected outcome of treatment and for understanding patients’ perceptions.
1. Introduction
Treatment for bone metastatic disease is often palliative and
aims tomaintain function and quality of life for the remaining
life span [1, 2]. Traditionally, studies focused on oncological
and surgical outcomes (e.g., survival and local recurrence),
but more emphasis has been placed on measuring impair-
ment and disability over the past decades [1, 3–5]. The
Musculoskeletal Tumor Society (MSTS) recognized this and
developed a system—the MSTS score—to evaluate function
in patients with musculoskeletal tumors [3]. The validity and
reliability of this tool were found to be acceptable when
applied to a sample of patients with malignant musculoskele-
tal tumors [6].The scoring system has been criticized because
it was developed to be completed by a clinician, instead
of measuring function as perceived by the patient [1, 7];
however, the MSTS score is still used because of its simplicity
and brevity (it consists of six items) [8, 9]. Studies in other
fields have demonstrated discrepancies between patient and
physician assessment of physical and mental health [10–13].
It is unclear whether the clinician derived MSTS score is rep-
resentative of the patients’ perceived function. We therefore
sought to evaluate if there is a difference between patient and
clinician reported physical function using the MSTS score in
a cohort of patients with bone metastases of the extremities.
Secondarily, we comparedMSTS domain scores and assessed
agreement between the clinician andpatient perceived scores.
2. Materials and Methods
2.1. Study Design. Our institutional review board approved
secondary use of prospectively collected data for the purpose
of this study, and a waiver of informed consent was obtained.
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We included data from the first 128 patients who completed a
set of physical function questionnaires for two prior studies.
These studies compared physical function questionnaires in
patients with lower (𝑛 = 100) and upper (𝑛 = 28) extremity
bone metastases, myeloma, or lymphoma [14]. Only English-
speaking patients aged 18 years or above who were able to
provide informed consent were approached for these studies.
Patients were enrolled between June 2014 and September
2015 from two orthopaedic oncology clinics. Patients were
included regardless of previous treatment and disease stage
[14]. Seventeen patients declined participation for the initial
study, and three patientswere excluded because of incomplete
questionnaires.
An ante hoc sample size calculation determined that we
would need a minimum of 128 patients to find an effect size
of 0.25 with an alpha of 0.05 and power of 0.80 using a paired
𝑡-test comparing the clinician reported MSTS score with the
patient perceived MSTS score.
2.2. Outcome Measures. Our primary outcome measure was
the Musculoskeletal Tumor Society (MSTS) score, intro-
duced in 1983 and modified in 1993 [3]. This scoring system
was developed to be completed by a clinician—physician or
physician extender—and it aims to assess physical function
in patients with lower and upper extremity tumors. The
modified version (1993) of the MSTS score consists of six
domains, each scored on a scale from 0 to 5, with a higher
score indicating better function.The total score, ranging from
0 to 30, can be transformed to a point scale of 0 to 100. There
are two versions: one for lower extremity tumors and one for
upper extremity tumors. These versions have three domains
in common, pain, function, and emotional acceptance, and
three region specific domains. The region specific domains
for the lower extremity are use of supports, walking ability,
and gait.The region specific domains for the upper extremity
are hand-positioning, dexterity, and lifting ability. Patients
completed one of the two versions based on the location of
their most disabling bone metastasis.
In addition, patients completed questions about their
level of education, marital status, presence of other disabling
conditions, prior treatment, and other bone or visceral
metastases. Prior treatment and presence of other metastases
were also derived from medical records. We extracted age,
sex, race, and location of bone metastasis from the medical
records.
Two research fellows (SJ and EvR)—blinded to the
patients’ answers—independently completed theMSTS score
based on the clinicians’ report in the medical record of the
patient; we used the report that was written at the time
(or within a few days) of survey completion by the patient.
Reports completed by the orthopaedic oncologist, medical
oncologist, and physical therapist were used to complete the
MSTS score. We averaged the scores assigned by the two
researchers per domain and for the overall MSTS score. To
assess reliability of extracting this data frommedical records,
we assessed difference in overall MSTS score and domain
scores between researchers and assessed their interobserver
agreement.
2.3. Statistical Analysis. We used frequencies with percent-
ages to describe categorical variables and median with
interquartile range for continuous variables as histograms
suggested nonnormality.
The nonparametric Wilcoxon signed rank test was used
to assess the difference between patient and clinician domain
scores and overall MSTS scores as data was not normally
distributed.
We assessed the relationship between the patient and
clinician MSTS and domain scores using both Spearman
rank correlation and intraclass correlation (ICC). Spearman
rank correlation determines the relationship between two
variables (range: −1 to 1): a score of 1 indicates a perfect
correlation, 0 indicates no correlation, and −1 indicates a
perfect inverse correlation. We used bootstrapping (number
of resamples: 1,000) to calculate 𝑝 values and 95% confidence
intervals for the Spearman rank correlation coefficients. The
intraclass correlation coefficient also assesses a relationship
between two variables but accounts for discrepancy in mea-
surements and therefore measures absolute agreement. We
calculated the ICC through a two-way mixed-effects model
with absolute agreement for the overall MSTS score and
the domain scores. As with the Spearman rank correlation
coefficient, an ICC of 1 reflects perfect agreement, whereas
0 reflects no agreement.
Additionally, we assessed difference in domain and total
scores between the two researchers using the Wilcoxon
signed rank test and assessed their interobserver agreement
per domain and overall score using the ICC.
2.4. Patient Characteristics. The median age was 63 years
(interquartile range [IQR]: 55 to 71) and the study included
74 (58%) women. The majority had a metastatic lesion in the
lower extremity (78% [100/128]). Eighty (63%) patients had
previous surgery, and 72 (56%) had previous radiotherapy
(Table 1). Breast was the most common primary tumor type
(26%) (Table 2).
3. Results
3.1. Patient Perceived Compared to Clinician MSTS Score.
We found that the clinicians’ MSTS score overestimated
the physical function as compared to the patient perceived
score. The median clinician MSTS score was 8 points higher
(median: 65 and IQR: 49 to 83) as compared to the patient
perceived score (median: 57 and IQR: 40 to 70) (𝑝 <
0.001) (Table 3). This difference also existed when analyzing
the lower extremity and upper extremity versions separately
(Table 3).
When comparing the three common domains, clinicians
scored higher for function (𝑝 < 0.001) and emotional
acceptance (𝑝 < 0.001) as compared to the patient perceived
score; however, there was no difference in assessment of pain
(𝑝 = 0.076). When comparing the three lower extremity
specific domains, clinicians scored higher for use of supports
(𝑝 = 0.003) and gait (𝑝 = 0.006) as compared to the patient
perceived score, and there was no difference in assessment
of walking ability (𝑝 = 0.102). When comparing the three
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Table 1: Demographics (𝑛 = 128).
Median (±interquartile range)
Age 63 (55–71)
𝑛 (%)
Sex
Women 74 (58)
Men 54 (42)
Race
Caucasian 117 (91)
African American 10 (8)
Asian 1 (1)
Education
High-school or less 41 (32)
College or Bachelor’s degree 53 (41)
Graduate or professional degree 34 (27)
Marital status
Married 84 (66)
Single 15 (12)
Widowed 15 (12)
Separated/divorced 9 (7)
Living with partner 5 (4)
Location of metastasis
Upper extremity 28 (22)
Humerus 21 (16)
Scapula 5 (4)
Clavicule 1 (1)
Radius 1 (1)
Lower extremity 100 (78)
Femur 71 (55)
Acetabulum 14 (11)
Pelvis 12 (9)
Tibia 2 (2)
Fibula 1 (1)
Other disabling conditions
Yes 37 (29)
No 90 (71)
Previous surgery for metastatic lesion
Yes 80 (63)
No 48 (38)
Previous radiotherapy for metastatic
lesion
Yes 72 (56)
No 53 (41)
Unknown 3 (2)
Multiple bones affected
Yes 61 (48)
No 55 (43)
Unknown 12 (9)
Visceral organs affected
Yes 39 (30)
No 78 (61)
Unknown 11 (9)
upper extremity specific domains, clinicians scored higher for
hand-positioning (𝑝 = 0.048) and lifting ability (𝑝 = 0.002)
Table 2: Tumor type (𝑛 = 128).
Bone metastases
Breast 33 (26)
Renal cell 17 (13)
Prostate 11 (8.6)
Lung 11 (8.6)
Melanoma 7 (5.5)
Leiomyosarcoma 5 (3.9)
Bladder 3 (2.3)
Thyroid 3 (2.3)
Colorectal 2 (1.6)
Hepatocellular 2 (1.6)
Stomach 1 (0.8)
Esophageal 1 (0.8)
Neuroendocrine 1 (0.8)
Sarcoma 1 (0.8)
Primary bone tumors
Myeloma 17 (13)
Lymphoma 13 (10)
as compared to the patient perceived score, and there was no
difference in assessment of dexterity (𝑝 = 0.890).
Agreement between the overall clinician score and the
patient perceived score was substantial (ICC: 0.66, 95% CI
0.43–0.79, and 𝑝 < 0.001) (Table 4). We found moderate
agreement for assessment of the common domains: pain
(ICC: 0.50) and function (ICC: 0.43), but no agreement
for emotional acceptance (ICC: 0.08). Agreement was sub-
stantial for assessment of the lower extremity specific use
of supports domain (ICC: 0.72) and moderate for walking
ability (ICC: 0.47) and gait (ICC: 0.48). We found substantial
agreement for the upper extremity specific hand-positioning
domain (ICC: 0.61), moderate for dexterity (ICC: 0.51), and
no agreement for lifting ability (ICC: 0.16). The Spearman
rank correlation coefficients were higher than the intraclass
correlation coefficients reflecting the discrepancy of scores
between the clinician and patient (Table 4).
3.2. Assessing Reliability of Extracting the Clinician MSTS
Score from Medical Records. We found no difference in
overall clinician MSTS score derived from medical records
between researchers (researcher 1: median: 67 and IQR: 48–
90 and researcher 2: median: 63 and IQR: 50–82; 𝑝 =
0.142), nor did we find a difference between researchers for
deriving any of the medical record based domain scores. The
interobserver agreement between researchers for the overall
clinician MSTS score was substantial (ICC: 0.78, 95% CI
0.70–0.84, and𝑝 < 0.001).These analyses indicate substantial
reliability for deriving the clinician MSTS score from the
medical record.
4. Discussion
The MSTS scoring tool evaluates function in patients with
extremity tumors and is developed to be completed by the
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Table 3: MSTS score comparison.
Patient score Clinician score
𝑝 value
Median (±interquartile range) Median (±interquartile range)
Overall MSTS score 57 (40–70) 65 (49–83) <0.001
Lower extremity MSTS score 57 (37–70) 63 (48–84) <0.001
Upper extremity MSTS score 63 (53–73) 74 (58–85) <0.001
MSTS common domains
Pain 4 (2–5) 3 (3-4) 0.076
Function 2 (2–4) 4 (3–5) <0.001
Emotional acceptance 2 (1–3) 4 (3-4) <0.001
Lower extremity specific domains
Use of supports 1 (1–5) 3 (1–5) 0.003
Walking ability 4 (3-4) 3 (3-4) 0.102
Gait 3 (2–4) 4 (3–5) 0.006
Upper extremity specific domains
Hand-positioning 4 (1–5) 4 (3-4) 0.048
Dexterity 5 (3–5) 4 (4-5) 0.890
Lifting ability 3 (1–4) 4 (3-4) 0.002
Bold indicates significant difference (two-tailed 𝑝 value below 0.05).
Table 4: Comparison of interobserver reliability.
Patient score compared with clinician
score
𝑝 value
Patient score compared with
clinician score
𝑝 value
Spearman correlation coefficient
(95% confidence interval)∗
Intraclass correlation coefficient
(95% confidence interval)
Overall MSTS score 0.74 (0.64–0.83) <0.001 0.66 (0.43–0.79) <0.001
Lower extremity MSTS score 0.71 (0.59–0.82) <0.001 0.64 (0.42–0.78) <0.001
Upper extremity MSTS score 0.82 (0.68–0.97) <0.001 0.74 (0.25–0.90) <0.001
MSTS common domains
Pain 0.50 (0.35–0.64) <0.001 0.50 (0.36–0.62) <0.001
Function 0.52 (0.38–0.66) <0.001 0.43 (0.23–0.59) <0.001
Emotional acceptance 0.16 (−0.02–0.35) 0.073 0.08 (−0.06–0.21) 0.105
Lower extremity specific domains
Use of supports 0.74 (0.62–0.86) <0.001 0.72 (0.60–0.81) <0.001
Walking ability 0.54 (0.39–0.68) <0.001 0.47 (0.30–0.61) <0.001
Gait 0.49 (0.34–0.63) <0.001 0.48 (0.29–0.62) <0.001
Upper extremity specific domains
Hand-positioning 0.84 (0.72–0.96) <0.001 0.61 (0.29–0.81) <0.001
Dexterity 0.51 (0.18–0.85) 0.003 0.51 (0.18–0.74) 0.003
Lifting ability 0.30 (−0.07–0.66) 0.110 0.16 (−0.12–0.46) 0.124
Bold indicates significant correlation (two-tailed 𝑝 value below 0.05).
∗95% confidence interval calculated through bootstrapping (1,000 resamples).
clinician [3]. It is unclear how this clinician-based score
relates to the patients perceived function. We therefore
compared the MSTS score as completed by the patient
with a medical record based clinician reported MSTS score
and assessed discrepancies and agreement. We found that
the clinicians’ MSTS score overestimated physical function
as compared to the patient completed MSTS score. This
discrepancy was the largest for the common overall function
and emotional acceptance domains but was absent for the
pain domain.
This study has limitations. First, we based theMSTS score
on review of information provided by the clinician in the
medical records; however, the MSTS score was developed
to be completed by a clinician at time of the consultation.
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We see this as an important limitation and explored its
possible consequences by assessing discrepancies and inter-
observer agreement between two researchers who indepen-
dently derived these data from medical records. There was
no discrepancy between the researchers for the overall MSTS
score and their interobserver agreement was substantial;
this suggests reproducible assessment of the MSTS score
based on the medical record. Previous studies used the same
methodology to extract an MSTS score from information
in the medical record [15–17]. In addition, the judgment of
the two research fellows might have been different from the
judgment of the attending surgeon. Future prospective study
should therefore compare the patient completed MSTS score
with an MSTS score completed by the clinician at time of
the consultation. Second, patients might havemisunderstood
specific items or answer options as the scoring system is not
developed to be completed by a patient and not validated in
a patient sample. We considered this as a limitation but feel
that this did not compromise our results, as we believe that
erroneous answers would have occurred in both directions
(i.e., better andworse).Third, theMSTS score is developed for
evaluation of functional status in all musculoskeletal tumor
types. Patient demographics differ per tumor type and we
only studied a sample of patients with bone metastases; this
limits the generalizability of our results to this specific pop-
ulation. Future study might help elucidate the discrepancy
between patient and physician perceived function in primary
bone tumors.
Previous studies in other fields also demonstrated an
overestimation of patients’ physical and mental health when
estimated by a clinician as compared to the patients’ per-
ception [10, 13, 18]. Nelson et al. [10] demonstrated in
1,101 primary care patients that 12% rated major physical
limitations in the preceding month, while only 4.4% of the
patients were rated as such by their primary care physician.
This study also demonstrated that 9% rated major emotional
limitations, while only 5% were rated as such by their
physician. Rosenberger et al. [18] demonstrated that physi-
cians overestimated function and underestimated pain in 98
patients who underwent surgical anterior cruciate ligament
reconstruction or meniscectomy. In line with these previous
studies, we found the largest discrepancy for assessment of
the function and emotional acceptance domains in our study.
However, we found no difference for the pain domain. Pain
level in theMSTS score is based on the amount of pain and the
degree of disability it causes; this might explain why we did
not find difference in pain score. Despite the discrepancies,
clinicians’ estimates do correlate reasonably well with patient
scores for the overall MSTS score and domain scores, except
for emotional acceptance and lifting ability. This means that
clinicians recognize worse overall function as perceived by
the patient; however, the clinician tends to underestimate its
impact. Assessment of emotional acceptance by the clinician
does not correlate with the patients’ perception, which might
be explained by the subjectivity and complexity of this
measure. Lifting ability is a relatively objective measure and
the absence of correlation between the patient and clinician
score might have been a result of the small sample size (28
upper extremity patients).
The discrepancy between the clinicians’ assessment and
patients perception of health and symptoms can have several
consequences. First, surgeons have an important role in
counseling their patients regarding expected outcome after
treatment. It is important for them to understand patients’
perspectives about outcome to educate future patients. For
example, patients might be less satisfied, if their expectations
are not met or when recovery is slower than expected [18].
Second, patients might feel misunderstood or unheard by
their physician. A previous study demonstrated that con-
cordance (so called dyadic agreement) between the patients’
and physicians’ perceptions of health and symptoms are
associatedwith higher patient satisfaction [19]. Another study
demonstrated that dissatisfaction of the patient leads to less
compliancewith treatment recommendations and potentially
jeopardizes patients’ health and outcome [20]. A review of
plaintiff depositions demonstrated that delivering informa-
tion poorly and failure to empathize with the patients’ or
family’s perspective are common causes of medical litigation
[21, 22]. Third, a clinician might be biased towards certain
treatments; this might compromise comparison of clinician
reported outcomes across treatment options in prospective
studies and nonblinded clinical trials. Fourth, overestimating
outcomes tends to breed an attitude of complacency and iner-
tia among clinicians which could preclude further improve-
ment. Fifth, third-party payers may use reported (overesti-
mated) outcomes to dissuade costly innovation and research.
Capturing patient reported outcome measures, question-
naires completed by the patient, using validated instruments
for both research purposes and day-to-day clinical practice is
key. Previous studies demonstrated that use of information
from patient reported outcome measures leads to better
communication and decision making between doctors and
patients and improves satisfaction [11, 23, 24]. However, this
does not mean that clinician measures are uninformative.
Measuring pathophysiology and impairment (e.g., range
of motion, strength, and stability), in addition to patient
reported outcome measures (e.g., symptoms and disability),
will help us to better understand patient perceptions and
inform them about prognosis and outcome of different
treatment options.
In conclusion, clinician reports overestimate function as
compared to the patient perceived score. This is important
to acknowledge when informing patients about the expected
outcome of treatment and to understand patients’ percep-
tions. Our study reinforces the need for obtaining patient
reported outcomes using validated methods in orthopaedic
oncology.
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